Amundi Raises Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Amundi grew its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 187.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 25,669 shares of the company’s stock after acquiring an additional 16,737 shares during the quarter. Amundi’s holdings in Prestige Consumer Healthcare were worth $1,909,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in PBH. Kestra Investment Management LLC purchased a new stake in Prestige Consumer Healthcare during the 4th quarter valued at approximately $27,000. Huntington National Bank increased its holdings in shares of Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares during the period. GAMMA Investing LLC raised its stake in shares of Prestige Consumer Healthcare by 18.9% during the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock worth $108,000 after purchasing an additional 220 shares during the last quarter. KBC Group NV lifted its holdings in shares of Prestige Consumer Healthcare by 28.3% during the fourth quarter. KBC Group NV now owns 2,048 shares of the company’s stock worth $160,000 after purchasing an additional 452 shares during the period. Finally, Blue Trust Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 24.8% during the fourth quarter. Blue Trust Inc. now owns 2,190 shares of the company’s stock worth $158,000 after purchasing an additional 435 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on PBH. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research report on Monday, December 9th. DA Davidson increased their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Oppenheimer lifted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $92.60.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $84.87 on Tuesday. The firm has a 50 day moving average of $81.67 and a 200-day moving average of $78.38. The company has a market cap of $4.20 billion, a price-to-earnings ratio of 19.88, a PEG ratio of 2.69 and a beta of 0.46. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.